The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning

2017 ◽  
Vol 32 (10) ◽  
pp. 1474-1478 ◽  
Author(s):  
Elisa Frisaldi ◽  
Elisa Carlino ◽  
Maurizio Zibetti ◽  
Diletta Barbiani ◽  
Francesca Dematteis ◽  
...  
2020 ◽  
pp. 303-332
Author(s):  
Fabrizio Benedetti

This chapter is dedicated to motor disorders, first and foremost Parkinson’s disease, the area together with pain where most of the knowledge about the mechanisms of the placebo effect comes from. The placebo effect in Parkinson’s disease is mediated by dopamine release in the striatum and is associated with changes in activity of neurons in the subthalamic nucleus, substantia nigra pars reticulata, and motor thalamus. Deceptive verbal instructions about changes in drug dosage can affect the pharmacological effect of levodopa in the treatment of Parkinson’s disease. The therapeutic effects of deep brain stimulation are powerfully modulated by placebos. Migraine is another disease of the nervous system that shows very high rates of improvement in patients who received placebo, although the mechanisms are little understood. Other neurological diseases, like epilepsy, show improvements in placebo groups, but the mechanisms are not known.


2002 ◽  
Vol 25 (6) ◽  
pp. 302-306 ◽  
Author(s):  
R de la Fuente-Fernández

Author(s):  
Sarah Lidstone ◽  
A Jon Stoessl ◽  
Raul de la Fuente-Fernandez

2018 ◽  
Vol 52 ◽  
pp. 17-23 ◽  
Author(s):  
Gaetano Barbagallo ◽  
Rita Nisticò ◽  
Basilio Vescio ◽  
Antonio Cerasa ◽  
Giuseppe Olivadese ◽  
...  

2006 ◽  
Vol 56 (4) ◽  
pp. 222-229 ◽  
Author(s):  
Felipe Fregni ◽  
Paulo S. Boggio ◽  
Felix Bermpohl ◽  
Fernanda Maia ◽  
Sergio P. Rigonatti ◽  
...  

2015 ◽  
Vol 357 ◽  
pp. e271-e272
Author(s):  
C. Shin ◽  
S. Hahn ◽  
B. Park ◽  
J. Kim ◽  
E. Park ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document